Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Letter to the Editor

Volume 10, Number 10, October 2018, pages 796-797


Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors

Figure

Figure 1.
Figure 1. Correlations between weight changes and hazard ratios in eight clinical studies. Data plotted with diamonds were obtained from the relevant literature. Data on the body weight changes in the EMPA-REG OUTCOME study were obtained from the figure in the supplementary data and estimated as being a mean of -2 kg. From left to right: SUSTAIN-6, semaglutide 1 mg; SUSTAIN-6, semaglutide 0.5 mg [7]; LEADER [6]; EMPA-REG OUTCOME [4]; CANVAS [5]; EXCEL [9]; ELIXA [8]; SAVOR-TIMI53 [1] and EXAMINE [2]. The TECOS study [3] was excluded, as there were no data on the body weight changes.